Global Ganja Report

As the cannabis industry is embraced by corporate power and finance capital, the patenting of strains, products and applications is an increasing concern. But the international patchwork of legality makes for a confusing environment. Illegality has served as a paradoxical break on privatizing of varieties. Growers and advocates are devising means to protect the genetic commons in the new cannabis order.

So-called "smokable hemp" is suddenly available in shops from coast to coast, legal under terms of last year's Farm Bill. But law enforcement is consternated, conservative politicians are apoplectic, and legislation is being prepared to ban the stuff at the state level. Is this permissible under federal law?

Researchers are exploring the connection between cannabinoids and dopamine in the human brain, and particularly how THC affects our "reward system"—key to such phenomena as motivation, addiction and euphoria. Investigations are revealing both potential for treatments of psychiatric disorders as well as possible risks from heavy use, especially among the young.

With the fall of Italy’s far-right government, advocates are hoping the path may be cleared now for the country to become Europe's first to formally legalize cannabis. Meanwhile, thanks to a loophole in the law, low-THC varieties are sold openly in shops across the country. And Italy’s internal THC limit is actually slightly higher than the ultra-cautious European Union standard.

With the legal cannabis market increasingly dominated by "Big Bud," more Canadians are turning to homegrown—both for reasons of economy and an ethic of self-sufficiency. And they are fighting in the courts and the public squares for their right to do so—challenging both the federal limit on plants per household and efforts by two provinces to ban homegrown outright. So far, they are winning. 

The US Surgeon General has launched a new campaign hyping the supposed dangers of cannabis—a further disappointment for activists who held out hope that Trump harbored libertarian instincts and would legalize. All too predictably, the anti-legalization assumptions behind the new campaign are amply refuted by actual research.

Over the past weeks, dozens of people across several states have experienced serious lung problems, even requiring hospitalization, apparently after using vape cartridges. It is unclear if cannabis products were at issue in all such cases, and authorities are still investigating. But the illicit market in unregulated knock-off dab carts may be to blame.

In Washington state, glitches in the "seed-to-sale" tracking system nearly paralyzed the cannabis industry statewide last month, costing retailers hundreds of thousands of dollars and forcing temporary lay-offs of employees. Similar headlines have been seen from across the country's legalized states—pointing to a persistent issue.